U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada

EQS-News: Formycon AG / Key word(s): Miscellaneous U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada 25.06.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // June 25, 2025

U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada
 

• Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB203/AHZANTIVE in the United States and Canada
• Formycon’s major shareholder ATHOS KG directly supports the commercialization of FYB203/AHZANTIVE by leading the Series A financing of Valorum
   

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) today announces that Klinge Biopharma GmbH (Klinge), the exclusive owner of the global commercialization rights of FYB203/AHZANTIVE¹ (aflibercept-mrbb), Formycon’s biosimilar to Eylea², concluded an exclusive license agreement with U.S. biosimilars specialist Valorum Biologics LLC (“Valorum”) for the commercialization of FYB203/AHZANTIVE in the United States and Canada.

Upon signature of the agreement, Klinge is eligible to receive upfront payments and milestone payments, plus royalties on net sales. Formycon will participate in the mid-single-digit to low-double-digit percentage range in all payment streams to Klinge resulting from this agreement. Furthermore, Formycon will act as authorized designee to organize the supply chain for FYB203/AHZANTIVE and will receive additional service payments and a volume-based profit component for organizing the commercial market supply on behalf of Klinge.

Valorum is a biosimilar commercialization specialist established by experienced industry leaders including past presidents of AmerisourceBergen, Cardinal Health and General Manager of McKesson, respectively. The company is focused on best-in-class commercialization of biosimilars in the U.S. to improve access, reach and cost savings for the healthcare system. Valorum has built a team with unparalleled experience and established networks across the U.S. pharmaceutical market and will be well positioned to maximize the commercial potential of FYB203/AHZANTIVE.The team has collectively launched several multi-billion-dollar pharmaceutical products within large pharmaceutical organizations such as Johnson & Johnson, Merck and Roche in the past.